Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spain to reimburse Intelence

This article was originally published in Scrip

Executive Summary

Spain is to reimburseTibotec's Intelence (etravirine) for HIV patients who have failed on other antiretrovirals. 2,000 patients in Spain could benefit from the non-nucleoside reverse transcriptase inhibitor, which has a manufacturer's selling price of €450 there, says the health ministry. It will be dispensed in hospitals in 200mg doses. The European Commission approved Intelence in August and the company has since launched the drug in Germany, Austria, France, the UK, Finland, Denmark, Sweden and Poland. Outside the EU, Switzerland, Russia, Liechtenstein, the US, Canada, Mexico, Argentina, Colombia, Bolivia, Australia, Hong Kong and South Korea have also approved the drug. Tibotec is part ofJohnson & Johnson.

You may also be interested in...



Investors Spooked By High Prices For Advanced Therapies

To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.

Cost Offsets Crucial For Uptake Of Advanced Therapies

To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.

Australian Funding Commitment For New Medicines Wins Industry Thumbs Up

The pharma and biotech industries have welcomed Australia’s coronavirus recovery budget, which also sets aside funding for research into COVID-19 vaccines and makes positive changes to R&D tax incentives.

Topics

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel